EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Novel Approach for Treating Diabetes in a Patient With the Heterozygous Pathogenic Variant R46Q in the Insulin Gene

Kristina Laugesen iD, Søren Gregersen, Julie Støy

JCEM Case Reports · 27.06.2024 · 2 (7)

DOI: 10.1210/jcemcr/luae134 ↗

Kurz gefasst

Fallbericht in der Zeitschrift JCEM Case Reports, online erschienen am 18.07.2024. Verfasst von Kristina Laugesen und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Biochemistry, Aarhus University Hospital, 8200 Aarhus, Denmark. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 8 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Steno Diabetes Center Aarhus, Novo Nordic Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Maturity-onset diabetes of the young (MODY) is a monogenic disorder of glucose homeostasis with several subtypes, each defined by a distinct genetic etiology. Heterozygous pathogenic variants in the insulin gene are rare causes of MODY, and optimal treatment strategies remain uncertain. Herein we describe a patient with diabetes caused by the heterozygous pathogenic variant R46Q in the insulin gene and the glycemic response to selected antidiabetic treatment regimens. The R46Q pathogenic variant leads to secretion of both mutant and wild-type insulin. In vitro, the mutant insulin is associated with a lower insulin-receptor affinity compared with wild-type insulin and a decline in wild-type insulin secretion. In our patient, treatment with a combination of long- and short-acting insulin led to a decline in hemoglobin A1C (HbA1c), although not to the recommended target. A shift to metformin and subsequent add-on of a sodium-glucose cotransporter 2 inhibitor (SGLT2i) resulted in HbA1c levels of less than 7% (53 mmol/mol) and durable glycemic control. Continuous glucose monitoring and oral glucose tolerance tests confirmed that treatment with metformin and SGLT2i was superior to treatment with insulin. In conclusion, diabetes caused by the pathogenic variant R46Q in the insulin gene may be effectively treated with noninsulin.

Schlagwörter

Stichwörter der Autor:innen

MODYinsulin gene mutationmaturity-onset diabetes of the youngmetforminmonogenetic diabetessodium-glucose cotransporter 2 inhibitor

Autor:innen und Institutionen

  • Department of Clinical Biochemistry, Aarhus University Hospital, 8200 Aarhus, Denmark.
  • Steno Diabetes Center Aarhus, Aarhus University Hospital, 8200 Aarhus, Denmark.
  • Department of Clinical Medicine, Aarhus University, 8000 Aarhus, Denmark.

ORCID-Profile: Kristina Laugesen

Förderung

  • Steno Diabetes Center Aarhus
  • Novo Nordic Foundation

Zitieren

APA

Laugesen, K., Gregersen, S., & Støy, J. (2024). Novel Approach for Treating Diabetes in a Patient With the Heterozygous Pathogenic Variant R46Q in the Insulin Gene. JCEM Case Reports, 2(7). https://doi.org/10.1210/jcemcr/luae134

Vancouver

Laugesen K, Gregersen S, Støy J. Novel Approach for Treating Diabetes in a Patient With the Heterozygous Pathogenic Variant R46Q in the Insulin Gene. JCEM Case Reports. 2024;2(7). doi:10.1210/jcemcr/luae134

BibTeX
@article{Laugesen2024,
  author = {Laugesen, Kristina and Gregersen, Søren and Støy, Julie},
  title = {Novel Approach for Treating Diabetes in a Patient With the Heterozygous Pathogenic Variant R46Q in the Insulin Gene},
  journal = {JCEM Case Reports},
  year = {2024},
  volume = {2},
  number = {7},
  doi = {10.1210/jcemcr/luae134}
}
Kostenlos starten →